

Ardeschir Ghofrani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3367351/publications.pdf>

Version: 2024-02-01

510
papers

54,821
citations

2318

98
h-index

1496

219
g-index

580
all docs

580
docs citations

580
times ranked

25311
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Heart Journal</i> , 2016, 37, 67-119. | 1.0 | 5,074 |
| 2 | Updated Clinical Classification of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D34-D41. | 1.2 | 2,865 |
| 3 | 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 903-975. | 3.1 | 2,415 |
| 4 | Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2005, 353, 2148-2157. | 13.9 | 2,237 |
| 5 | Inhaled Iloprost for Severe Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2002, 347, 322-329. | 13.9 | 1,626 |
| 6 | Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 809-818. | 13.9 | 1,168 |
| 7 | Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 319-329. | 13.9 | 1,144 |
| 8 | Riociguat for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 330-340. | 13.9 | 1,120 |
| 9 | Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 117, 3010-3019. | 1.6 | 967 |
| 10 | Tadalafil Therapy for Pulmonary Arterial Hypertension. <i>Circulation</i> , 2009, 119, 2894-2903. | 1.6 | 956 |
| 11 | Reversal of experimental pulmonary hypertension by PDGF inhibition. <i>Journal of Clinical Investigation</i> , 2005, 115, 2811-2821. | 3.9 | 917 |
| 12 | Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 834-844. | 13.9 | 906 |
| 13 | Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 2522-2533. | 13.9 | 790 |
| 14 | Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. <i>Lancet</i> , The, 2002, 360, 895-900. | 6.3 | 720 |
| 15 | Chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801915. | 3.1 | 607 |
| 16 | Mechanisms of disease: pulmonary arterial hypertension. <i>Nature Reviews Cardiology</i> , 2011, 8, 443-455. | 6.1 | 605 |
| 17 | Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2127-2134. | 1.2 | 506 |
| 18 | Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2546-2552. | 1.2 | 498 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , 2017, 50, 1700740. | 3.1 | 489 |
| 20 | Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 1128-1138. | 1.6 | 482 |
| 21 | Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 689-702. | 21.5 | 471 |
| 22 | Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S78-S84. | 1.2 | 463 |
| 23 | Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension. <i>Annals of Internal Medicine</i> , 2002, 136, 515. | 2.0 | 446 |
| 24 | Imatinib for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2005, 353, 1412-1413. | 13.9 | 440 |
| 25 | Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 600-607. | 2.5 | 369 |
| 26 | Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2003, 42, 158-164. | 1.2 | 359 |
| 27 | Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013, 168, 871-880. | 0.8 | 357 |
| 28 | Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension. <i>Annals of Internal Medicine</i> , 1996, 124, 820. | 2.0 | 347 |
| 29 | Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1171-1177. | 2.5 | 331 |
| 30 | Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature. <i>Circulation Research</i> , 2007, 101, 258-267. | 2.0 | 317 |
| 31 | Anticoagulation and Survival in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 57-65. | 1.6 | 317 |
| 32 | A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2000, 35, 176-182. | 1.2 | 296 |
| 33 | Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 897-908. | 2.5 | 296 |
| 34 | Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. <i>Cell</i> , 2011, 147, 293-305. | 13.5 | 293 |
| 35 | ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002828. | 3.1 | 287 |
| 36 | Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction. <i>Circulation</i> , 2013, 128, 502-511. | 1.6 | 286 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. <i>Nature Communications</i> , 2018, 9, 1416. | 5.8 | 279 |
| 38 | Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19093-19098. | 3.3 | 273 |
| 39 | Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp. <i>Annals of Internal Medicine</i> , 2004, 141, 169. | 2.0 | 271 |
| 40 | Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 1139-1141. | 2.5 | 265 |
| 41 | Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). <i>European Respiratory Journal</i> , 2015, 45, 1293-1302. | 3.1 | 247 |
| 42 | Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 140, 1274-1283. | 0.4 | 237 |
| 43 | Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 39-45. | 2.5 | 230 |
| 44 | Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1971-1981. | 1.2 | 227 |
| 45 | Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009047. | 1.3 | 222 |
| 46 | The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 957-967. | 0.3 | 221 |
| 47 | Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2008, 32, 881-891. | 3.1 | 216 |
| 48 | First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. <i>European Respiratory Journal</i> , 2009, 33, 785-792. | 3.1 | 216 |
| 49 | Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. <i>European Respiratory Journal</i> , 2010, 36, 792-799. | 3.1 | 212 |
| 50 | 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 177. | 0.4 | 210 |
| 51 | Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling. <i>Circulation</i> , 2006, 113, 286-295. | 1.6 | 208 |
| 52 | Inhibition of MicroRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 409-419. | 2.5 | 206 |
| 53 | Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. <i>Circulation</i> , 2009, 119, 1747-1757. | 1.6 | 205 |
| 54 | Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 785-794. | 5.2 | 201 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Sildenafil treatment for portopulmonary hypertension. <i>European Respiratory Journal</i> , 2006, 28, 563-567. | 3.1 | 199 |
| 56 | Safety and efficacy of exercise training in various forms of pulmonary hypertension. <i>European Respiratory Journal</i> , 2012, 40, 84-92. | 3.1 | 199 |
| 57 | Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. <i>European Respiratory Journal</i> , 2008, 32, 1639-1651. | 3.1 | 184 |
| 58 | Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015, 46, 405-413. | 3.1 | 184 |
| 59 | Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. <i>Free Radical Biology and Medicine</i> , 2004, 36, 1279-1288. | 1.3 | 183 |
| 60 | Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 160119. | 3.0 | 183 |
| 61 | Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. <i>European Respiratory Journal</i> , 2017, 49, 1602409. | 3.1 | 178 |
| 62 | Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). <i>European Respiratory Journal</i> , 2015, 45, 1303-1313. | 3.1 | 174 |
| 63 | A Functional Single-Nucleotide Polymorphism in the <i>TRPC6</i> Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2009, 119, 2313-2322. | 1.6 | 173 |
| 64 | Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 154, 57-62. | 2.5 | 171 |
| 65 | Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 808-817. | 2.5 | 170 |
| 66 | Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2007, 30, 922-927. | 3.1 | 163 |
| 67 | Activation of TRPC6 channels is essential for lung ischaemia-induced reperfusion induced oedema in mice. <i>Nature Communications</i> , 2012, 3, 649. | 5.8 | 162 |
| 68 | Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. <i>FASEB Journal</i> , 2005, 19, 1175-1177. | 0.2 | 158 |
| 69 | Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload. <i>Circulation: Heart Failure</i> , 2019, 12, e005512. | 1.6 | 158 |
| 70 | Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2018, 266, 229-235. | 0.8 | 154 |
| 71 | Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 294-302. | 2.5 | 153 |
| 72 | Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension. <i>Respiration</i> , 2011, 81, 394-401. | 1.2 | 151 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2007, 115, 2331-2339. | 1.6 | 139 |
| 74 | Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. <i>Circulation</i> , 2008, 118, 2081-2090. | 1.6 | 139 |
| 75 | Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1672-1681. | 1.2 | 135 |
| 76 | Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1219-1227. | 0.5 | 135 |
| 77 | Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1488-1496. | 1.2 | 134 |
| 78 | Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S68-S72. | 1.2 | 131 |
| 79 | Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 372-380. | 5.2 | 130 |
| 80 | Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , 2008, 32, 198-209. | 3.1 | 129 |
| 81 | The molecular targets of approved treatments for pulmonary arterial hypertension. <i>Thorax</i> , 2016, 71, 73-83. | 2.7 | 126 |
| 82 | Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension. <i>Chest</i> , 2003, 124, 1294-1304. | 0.4 | 124 |
| 83 | Tadalafil for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 60, 768-774. | 1.2 | 124 |
| 84 | COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 60, 2102311. | 3.1 | 124 |
| 85 | Targeting cancer with phosphodiesterase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 117-131. | 1.9 | 123 |
| 86 | Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238. | 5.2 | 122 |
| 87 | Prostacyclin and its analogues in the treatment of pulmonary hypertension. , 2004, 102, 139-153. | | 119 |
| 88 | Targeting non-malignant disorders with tyrosine kinase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 956-970. | 21.5 | 118 |
| 89 | Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 158-167. | 2.5 | 118 |
| 90 | New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D82-D91. | 1.2 | 113 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , 2017, 50, 1602425. | 3.1 | 113 |
| 92 | Simvastatin as a Treatment for Pulmonary Hypertension Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1106-1113. | 2.5 | 112 |
| 93 | Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1354-1365. | 1.1 | 108 |
| 94 | Pathophysiology and Treatment of High-Altitude Pulmonary Vascular Disease. <i>Circulation</i> , 2015, 131, 582-590. | 1.6 | 108 |
| 95 | Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 422-426. | 0.5 | 108 |
| 96 | Current and future treatments of pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , 2021, 178, 6-30. | 2.7 | 104 |
| 97 | Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1366-1375. | 0.3 | 103 |
| 98 | Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. <i>European Respiratory Journal</i> , 2001, 17, 14-19. | 3.1 | 100 |
| 99 | The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. <i>PLoS ONE</i> , 2012, 7, e43433. | 1.1 | 100 |
| 100 | Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 717-726. | 5.2 | 99 |
| 101 | Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2004, 94, 1101-1108. | 2.0 | 97 |
| 102 | Pulmonary Vascular Disease in the Developing World. <i>Circulation</i> , 2008, 118, 1758-1766. | 1.6 | 97 |
| 103 | Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 361-371. | 5.2 | 97 |
| 104 | Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1602493. | 3.1 | 97 |
| 105 | Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 632-643. | 0.3 | 95 |
| 106 | Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. <i>European Respiratory Journal</i> , 2011, 37, 1104-1118. | 3.1 | 93 |
| 107 | Impact of Mitochondria and NADPH Oxidases on Acute and Sustained Hypoxic Pulmonary Vasoconstriction. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 34, 505-513. | 1.4 | 90 |
| 108 | Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 118, 1195-1201. | 1.6 | 90 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing. <i>Circulation Research</i> , 2017, 121, 424-438. | 2.0 | 90 |
| 110 | Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 48, 1137-1149. | 3.1 | 89 |
| 111 | Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H ₂ O ₂ ?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 279, L683-L690. | 1.3 | 87 |
| 112 | Riociguat for pulmonary arterial hypertension associated with congenital heart disease. <i>Heart</i> , 2015, 101, 1792-1799. | 1.2 | 87 |
| 113 | Pulmonary Hypertension. <i>Deutsches A&#x0308;rztblatt International</i> , 2017, 114, 73-84. | 0.6 | 87 |
| 114 | Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 573-584. | 5.2 | 85 |
| 115 | Expression and Activity of Phosphodiesterase Isoforms during Epithelial Mesenchymal Transition: The Role of Phosphodiesterase 4. <i>Molecular Biology of the Cell</i> , 2009, 20, 4751-4765. | 0.9 | 84 |
| 116 | Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2009, 34, 132-137. | 3.1 | 83 |
| 117 | Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Respiratory Research</i> , 2013, 14, 104. | 1.4 | 83 |
| 118 | Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 188-196. | 2.5 | 82 |
| 119 | Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 71, 752-763. | 1.2 | 82 |
| 120 | Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. <i>ESC Heart Failure</i> , 2021, 8, 183-203. | 1.4 | 82 |
| 121 | Riociguat for the treatment of pulmonary hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 567-576. | 1.9 | 81 |
| 122 | Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smoke-induced Pulmonary Hypertension and Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1359-1373. | 2.5 | 80 |
| 123 | Nocturnal periodic breathing in primary pulmonary hypertension. <i>European Respiratory Journal</i> , 2002, 19, 658-663. | 3.1 | 79 |
| 124 | Fhl-1, a New Key Protein in Pulmonary Hypertension. <i>Circulation</i> , 2008, 118, 1183-1194. | 1.6 | 79 |
| 125 | Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. <i>Chest</i> , 2017, 151, 468-480. | 0.4 | 79 |
| 126 | ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 373-385. | 2.5 | 78 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Classical Transient Receptor Potential Channel 1 in Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1451-1459. | 2.5 | 77 |
| 128 | Cyclooxygenase Isoenzyme Localization and mRNA Expression in Rat Lungs. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 479-488. | 1.4 | 76 |
| 129 | Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clinical Microbiology and Infection, 2011, 17, 7-14. | 2.8 | 75 |
| 130 | Sleep apnea in precapillary pulmonary hypertension. Sleep Medicine, 2013, 14, 247-251. | 0.8 | 75 |
| 131 | Novel and Emerging Therapies for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 394-400. | 2.5 | 75 |
| 132 | Cardiac Magnetic Resonance Imaging-Based Right Ventricular Strain Analysis for Assessment of Coupling and Diastolic Function in Pulmonary Hypertension. JACC: Cardiovascular Imaging, 2019, 12, 2155-2164. | 2.3 | 75 |
| 133 | Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. European Respiratory Journal, 2007, 29, 713-719. | 3.1 | 74 |
| 134 | Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489. | 2.9 | 74 |
| 135 | Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1500-1506. | 2.5 | 73 |
| 136 | Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. European Respiratory Journal, 2004, 23, 321-326. | 3.1 | 72 |
| 137 | Oleic Acid Inhibits Alveolar Fluid Reabsorption. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 469-479. | 2.5 | 72 |
| 138 | Impairment of respiratory muscle function in pulmonary hypertension. Clinical Science, 2008, 114, 165-171. | 1.8 | 72 |
| 139 | Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respiratory Medicine, 2010, 104, 731-740. | 1.3 | 72 |
| 140 | p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 603-614. | 1.4 | 72 |
| 141 | Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Critical Care Medicine, 2002, 30, 2489-2492. | 0.4 | 69 |
| 142 | Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Science Translational Medicine, 2017, 9, . | 5.8 | 69 |
| 143 | Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47. | 1.0 | 69 |
| 144 | Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications, 2019, 10, 2204. | 5.8 | 69 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. <i>Free Radical Biology and Medicine</i> , 2012, 52, 1033-1042. | 1.3 | 68 |
| 146 | Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1802004. | 3.1 | 68 |
| 147 | Evaluation and Prognostic Relevance of Right Ventricular Arterial Coupling in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 116-119. | 2.5 | 68 |
| 148 | Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019, 139, 2440-2450. | 1.6 | 67 |
| 149 | Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. <i>Respiratory Research</i> , 2011, 12, 60. | 1.4 | 66 |
| 150 | Mitochondrial Hyperpolarization in Pulmonary Vascular Remodeling. Mitochondrial Uncoupling Protein Deficiency as Disease Model. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 358-367. | 1.4 | 66 |
| 151 | Amplified canonical transforming growth factor- β 2 signalling via heat shock protein 90 in pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017, 49, 1501941. | 3.1 | 66 |
| 152 | SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2017, 38, 1147-1155. | 1.0 | 65 |
| 153 | Thrombin Impairs Alveolar Fluid Clearance by Promoting Endocytosis of Na ⁺ ,K ⁺ -ATPase. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2005, 33, 343-354. | 1.4 | 64 |
| 154 | Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 824-832. | 1.1 | 64 |
| 155 | Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension. <i>European Respiratory Journal</i> , 2018, 51, 1701024. | 3.1 | 64 |
| 156 | More on Single-Beat Estimation of Right Ventriculoarterial Coupling in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 816-818. | 2.5 | 63 |
| 157 | Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 358-363. | 2.5 | 62 |
| 158 | Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S108-S117. | 1.2 | 62 |
| 159 | Function of NADPH Oxidase 1 in Pulmonary Arterial Smooth Muscle Cells After Monocrotaline-Induced Pulmonary Vascular Remodeling. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 2213-2231. | 2.5 | 62 |
| 160 | 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. <i>BioMed Research International</i> , 2015, 2015, 1-8. | 0.9 | 62 |
| 161 | Oxygen sensors in hypoxic pulmonary vasoconstriction. <i>Cardiovascular Research</i> , 2006, 71, 620-629. | 1.8 | 61 |
| 162 | The lectin-like domain of tumor necrosis factor- α improves alveolar fluid balance in injured isolated rabbit lungs*. <i>Critical Care Medicine</i> , 2008, 36, 1543-1550. | 0.4 | 61 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Pulmonary hypertension due to chronic lung disease: Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S45-S53. | 0.8 | 61 |
| 164 | PAR-2 Inhibition Reverses Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2012, 110, 1179-1191. | 2.0 | 61 |
| 165 | Effects of hypercapnia with and without acidosis on hypoxic pulmonary vasoconstriction. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L977-L983. | 1.3 | 60 |
| 166 | Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. <i>European Respiratory Journal</i> , 2012, 39, 119-124. | 3.1 | 60 |
| 167 | Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. <i>Intensive Care Medicine</i> , 1998, 24, 631-634. | 3.9 | 59 |
| 168 | NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L638-L645. | 1.3 | 59 |
| 169 | Microcirculatory Dysfunction in the Brain Precedes Changes in Evoked Potentials in Endotoxin-Induced Sepsis Syndrome in Rats. <i>Cerebrovascular Diseases</i> , 2007, 23, 140-147. | 0.8 | 59 |
| 170 | Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. <i>Respiratory Research</i> , 2011, 12, 99. | 1.4 | 59 |
| 171 | The Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis. <i>Science Translational Medicine</i> , 2011, 03, 87ra53. | 5.8 | 59 |
| 172 | Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 894-901. | 5.2 | 59 |
| 173 | Basic features of hypoxic pulmonary vasoconstriction in mice. <i>Respiratory Physiology and Neurobiology</i> , 2004, 139, 191-202. | 0.7 | 58 |
| 174 | Cellular pathophysiology and therapy of pulmonary hypertension. <i>Translational Research</i> , 2001, 138, 367-377. | 2.4 | 57 |
| 175 | Mediator generation and signaling events in alveolar epithelial cells attacked by <i>S. aureus</i> toxin. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 282, L207-L214. | 1.3 | 57 |
| 176 | Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. <i>European Respiratory Journal</i> , 2018, 52, 1800458. | 3.1 | 57 |
| 177 | Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study. <i>PLoS ONE</i> , 2015, 10, e0130072. | 1.1 | 57 |
| 178 | Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2022, 59, 2102024. | 3.1 | 57 |
| 179 | Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 937-948. | 5.2 | 57 |
| 180 | Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1130-1136. | 1.2 | 56 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 598-605. | 0.9 | 56 |
| 182 | Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 37-45. | 0.8 | 56 |
| 183 | Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. <i>European Respiratory Review</i> , 2009, 18, 35-41. | 3.0 | 55 |
| 184 | Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 1694-1700. | 2.5 | 54 |
| 185 | Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension. <i>Cerebrovascular Diseases</i> , 2006, 21, 194-200. | 0.8 | 54 |
| 186 | miR-223â€™IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. <i>Cardiovascular Research</i> , 2016, 111, 184-193. | 1.8 | 54 |
| 187 | Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. <i>Pulmonary Circulation</i> , 2018, 8, 1-6. | 0.8 | 54 |
| 188 | Quality of life in patients with chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2016, 48, 526-537. | 3.1 | 52 |
| 189 | Medical management of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 160107. | 3.0 | 52 |
| 190 | Effects of Mitochondrial Inhibitors and Uncouplers on Hypoxic Vasoconstriction in Rabbit Lungs. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003, 29, 721-732. | 1.4 | 51 |
| 191 | Diacylglycerol regulates acute hypoxic pulmonary vasoconstriction via TRPC6. <i>Respiratory Research</i> , 2011, 12, 20. | 1.4 | 51 |
| 192 | Effect of Macitentan on Hospitalizations. <i>JACC: Heart Failure</i> , 2015, 3, 1-8. | 1.9 | 51 |
| 193 | Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 600-609. | 1.0 | 50 |
| 194 | Hypoxia- and non-hypoxia-related pulmonary hypertension â€™ Established and new therapies. <i>Cardiovascular Research</i> , 2006, 72, 30-40. | 1.8 | 49 |
| 195 | Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. <i>European Respiratory Journal</i> , 2010, 36, 808-818. | 3.1 | 48 |
| 196 | Psoas Muscle Architectural Design, In Vivo Sarcomere Length Range, and Passive Tensile Properties Support Its Role as a Lumbar Spine Stabilizer. <i>Spine</i> , 2011, 36, E1666-E1674. | 1.0 | 48 |
| 197 | Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. <i>Scientific Reports</i> , 2018, 8, 1300. | 1.6 | 48 |
| 198 | Sex Differences in Right Ventricularâ€™Pulmonary Arterial Coupling in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1042-1046. | 2.5 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Increased neutrophil mediator release in patients with pulmonary hypertension "suppression by inhaled iloprost. <i>Thrombosis and Haemostasis</i> , 2003, 90, 1141-1149. | 1.8 | 47 |
| 200 | Arterial hypertension in a murine model of sleep apnea. <i>Journal of Hypertension</i> , 2014, 32, 300-305. | 0.3 | 47 |
| 201 | Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S20-S33. | 0.8 | 46 |
| 202 | Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2017, 151, 106-118. | 0.4 | 46 |
| 203 | Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2018, 18, 41. | 0.8 | 46 |
| 204 | Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. <i>European Respiratory Journal</i> , 2015, 46, 1084-1094. | 3.1 | 45 |
| 205 | The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. <i>European Journal of Clinical Investigation</i> , 2009, 39, 38-49. | 1.7 | 44 |
| 206 | Updated classification and management of pulmonary hypertension. <i>Heart</i> , 2010, 96, 552-559. | 1.2 | 44 |
| 207 | Hypoxic Pulmonary Hypertension in Mice with Constitutively Active Platelet-Derived Growth Factor Receptor β . <i>Pulmonary Circulation</i> , 2011, 1, 259-268. | 0.8 | 44 |
| 208 | The role of combination therapy in managing pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2014, 23, 469-475. | 3.0 | 44 |
| 209 | Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-7. | 0.8 | 44 |
| 210 | Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 276, L90-L95. | 1.3 | 43 |
| 211 | Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 50-56. | 1.1 | 43 |
| 212 | Burden of pulmonary arterial hypertension in Germany. <i>Respiratory Medicine</i> , 2010, 104, 902-910. | 1.3 | 43 |
| 213 | Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1692. | 1.2 | 43 |
| 214 | Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. <i>European Respiratory Journal</i> , 2009, 33, 861-870. | 3.1 | 42 |
| 215 | cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases. <i>Circulation</i> , 2011, 123, 1194-1204. | 1.6 | 42 |
| 216 | Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. <i>Frontiers in Physiology</i> , 2018, 9, 609. | 1.3 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Right ventricular function correlates of right atrial strain in pulmonary hypertension: a combined cardiac magnetic resonance and conductance catheter study. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 318, H156-H164. | 1.5 | 42 |
| 218 | A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 56, 2000513. | 3.1 | 42 |
| 219 | Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , 2019, 21, 352-359. | 2.9 | 40 |
| 220 | Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. <i>British Journal of Pharmacology</i> , 2021, 178, 90-107. | 2.7 | 40 |
| 221 | Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015, 46, 1711-1720. | 3.1 | 39 |
| 222 | The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature. <i>Frontiers in Immunology</i> , 2017, 8, 707. | 2.2 | 39 |
| 223 | Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). <i>Respiratory Research</i> , 2018, 19, 258. | 1.4 | 39 |
| 224 | Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1407-1420. | 2.5 | 39 |
| 225 | Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. <i>Science Advances</i> , 2020, 6, eaba0694. | 4.7 | 39 |
| 226 | Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. <i>BMC Pulmonary Medicine</i> , 2010, 10, 26. | 0.8 | 38 |
| 227 | Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 281, L1361-L1368. | 1.3 | 37 |
| 228 | Heme Oxygenase-2 and Large-Conductance Ca ²⁺ -activated K ⁺ Channels. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 353-364. | 2.5 | 37 |
| 229 | Prostacyclin Enhances Stretch-induced Surfactant Secretion in Alveolar Epithelial Type II Cells. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 846-851. | 2.5 | 36 |
| 230 | Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. <i>BMC Pulmonary Medicine</i> , 2008, 8, 25. | 0.8 | 36 |
| 231 | Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling. <i>PLoS ONE</i> , 2011, 6, e18136. | 1.1 | 36 |
| 232 | New horizons in pulmonary arterial hypertension therapies. <i>European Respiratory Review</i> , 2013, 22, 503-514. | 3.0 | 36 |
| 233 | Histological Characterization of Mast Cell Chymase in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. <i>Pulmonary Circulation</i> , 2014, 4, 128-136. | 0.8 | 36 |
| 234 | Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle. <i>Physiological Reports</i> , 2017, 5, e13146. | 0.7 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. American Journal of Human Genetics, 2018, 103, 144-153. | 2.6 | 36 |
| 236 | Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension. PLoS ONE, 2011, 6, e18883. | 1.1 | 36 |
| 237 | The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L658-L665. | 1.3 | 35 |
| 238 | Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. Respiratory Physiology and Neurobiology, 2010, 174, 282-291. | 0.7 | 35 |
| 239 | Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. International Journal of Cardiology, 2013, 167, 2630-2637. | 0.8 | 35 |
| 240 | Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H931-H938. | 1.5 | 34 |
| 241 | Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respiratory Research, 2005, 6, 128. | 1.4 | 34 |
| 242 | Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respiratory Research, 2007, 8, 4. | 1.4 | 34 |
| 243 | Mitochondrial cytochrome redox states and respiration in acute pulmonary oxygen sensing. European Respiratory Journal, 2010, 36, 1056-1066. | 3.1 | 34 |
| 244 | Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart, 2017, 103, 599-606. | 1.2 | 34 |
| 245 | Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-3. | 0.8 | 34 |
| 246 | Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 144, 149. | 2.0 | 33 |
| 247 | HbA1c in pulmonary arterial hypertension: A marker of prognostic relevance?. Journal of Heart and Lung Transplantation, 2012, 31, 1109-1114. | 0.3 | 33 |
| 248 | Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension. Pulmonary Circulation, 2017, 7, 20-37. | 0.8 | 33 |
| 249 | Short-term venoarterial extracorporeal membrane oxygenation for massive endobronchial hemorrhage after pulmonary endarterectomy. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 643-649. | 0.4 | 33 |
| 250 | Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE, 2018, 13, e0193226. | 1.1 | 33 |
| 251 | Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. Respiratory Research, 2005, 6, 86. | 1.4 | 32 |
| 252 | Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. Respiratory Physiology and Neurobiology, 2007, 159, 196-201. | 0.7 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | New potential diagnostic biomarkers for pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 1390-1396. | 3.1 | 32 |
| 254 | Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension. <i>Canadian Respiratory Journal</i> , 2017, 2017, 1-17. | 0.8 | 32 |
| 255 | Congenital erythropoietin over-expression causes anti-pulmonary hypertensive structural and functional changes in mice, both in normoxia and hypoxia. <i>Thrombosis and Haemostasis</i> , 2005, 94, 630-638. | 1.8 | 31 |
| 256 | Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. <i>Respiratory Research</i> , 2005, 6, 76. | 1.4 | 31 |
| 257 | Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L986-L995. | 1.3 | 31 |
| 258 | Acute Effects of Riociguat in Borderline or Manifest Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease. <i>Pulmonary Circulation</i> , 2015, 5, 296-304. | 0.8 | 31 |
| 259 | Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. <i>Respiratory Medicine</i> , 2017, 128, 50-56. | 1.3 | 31 |
| 260 | Endotoxin "priming" potentiates lung vascular abnormalities in response to Escherichia coli hemolysin: an example of synergism between endo- and exotoxin.. <i>Journal of Experimental Medicine</i> , 1994, 180, 1437-1443. | 4.2 | 30 |
| 261 | Riociguat for pulmonary hypertension. <i>Future Cardiology</i> , 2010, 6, 155-166. | 0.5 | 30 |
| 262 | A simple echocardiographic estimate of right ventricular-arterial coupling to assess severity and outcome in pulmonary hypertension on chronic lung disease. <i>European Respiratory Journal</i> , 2019, 54, 1802435. | 3.1 | 30 |
| 263 | Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , 2021, 12, 667602. | 1.3 | 30 |
| 264 | Differential Impact of Ultrasonically Nebulized Versus Tracheal-instilled Surfactant on Ventilation-Perfusion (V _E TM /Q _E TM) Mismatch in a Model of Acute Lung Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 152-159. | 2.5 | 29 |
| 265 | Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. <i>Respiratory Medicine</i> , 2009, 103, 1713-1718. | 1.3 | 29 |
| 266 | Dynamic hyperinflation during exercise in patients with precapillary pulmonary hypertension. <i>Respiratory Medicine</i> , 2012, 106, 308-313. | 1.3 | 29 |
| 267 | Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study. <i>European Respiratory Journal</i> , 2017, 49, 1602168. | 3.1 | 29 |
| 268 | REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 836-843. | 0.3 | 29 |
| 269 | REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 513-519. | 0.3 | 29 |
| 270 | Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. <i>BioMed Research International</i> , 2018, 2018, 1-9. | 0.9 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 748-756. | 0.3 | 29 |
| 272 | Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. <i>PLoS ONE</i> , 2015, 10, e0129327. | 1.1 | 29 |
| 273 | Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. <i>European Respiratory Journal</i> , 2008, 31, 599-610. | 3.1 | 28 |
| 274 | Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. <i>International Journal of Cardiology</i> , 2016, 216, 85-91. | 0.8 | 28 |
| 275 | Hypoxia-induced pulmonary hypertension: Different impact of iloprost, sildenafil, and nitric oxide. <i>Respiratory Medicine</i> , 2007, 101, 2125-2132. | 1.3 | 27 |
| 276 | A Combination Hybrid-Based Vaccination/Adoptive Cellular Therapy to Prevent Tumor Growth by Involvement of T Cells. <i>Cancer Research</i> , 2007, 67, 5443-5453. | 0.4 | 26 |
| 277 | Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1 studies. <i>Pulmonary Circulation</i> , 2018, 8, 1-4. | 0.8 | 26 |
| 278 | Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1235-1244. | 0.3 | 26 |
| 279 | Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. <i>Thrombosis and Haemostasis</i> , 2006, 95, 720-727. | 1.8 | 26 |
| 280 | Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. <i>European Journal of Heart Failure</i> , 2012, 14, 946-953. | 2.9 | 25 |
| 281 | The prognostic impact of thyroid function in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1427-1434. | 0.3 | 25 |
| 282 | Riociguat for treatment of pulmonary hypertension in COPD: a translational study. <i>European Respiratory Journal</i> , 2019, 53, 1802445. | 3.1 | 25 |
| 283 | Nitric Oxide (NO)-Dependent but Not NO-Independent Guanylate Cyclase Activation Attenuates Hypoxic Vasoconstriction in Rabbit Lungs. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 23, 222-227. | 1.4 | 24 |
| 284 | Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. <i>European Respiratory Journal</i> , 2002, 19, 664-671. | 3.1 | 24 |
| 285 | A Case Series of Patients with Severe Pulmonary Hypertension Receiving an Implantable Pump for Intravenous Prostanoid Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1196-1198. | 2.5 | 24 |
| 286 | Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension. <i>Lung</i> , 2017, 195, 489-496. | 1.4 | 24 |
| 287 | TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-7. | 0.8 | 24 |
| 288 | Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L896-L904. | 1.3 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 289 | Pharmacokinetics and Metabolism of Infused versus Inhaled Iloprost in Isolated Rabbit Lungs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 741-745. | 1.3 | 23 |
| 290 | Impact of S-Adenosylmethionine Decarboxylase 1 on Pulmonary Vascular Remodeling. <i>Circulation</i> , 2014, 129, 1510-1523. | 1.6 | 23 |
| 291 | NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. <i>Nature Metabolism</i> , 2020, 2, 532-546. | 5.1 | 23 |
| 292 | Evaluation of the prognostic value of electrocardiography parameters and heart rhythm in patients with pulmonary hypertension. <i>Cardiology Journal</i> , 2016, 23, 465-472. | 0.5 | 23 |
| 293 | Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 219-225. | 1.4 | 22 |
| 294 | An Evaluation of Fracture Stabilization Comparing Kyphoplasty and Titanium Mesh Repair Techniques for Vertebral Compression Fractures. <i>Spine</i> , 2010, 35, E768-E773. | 1.0 | 22 |
| 295 | Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2010, 11, 146. | 1.4 | 22 |
| 296 | Cardiovascular Syndrome (Ortner's Syndrome) Associated with Chronic Thromboembolic Pulmonary Hypertension and Giant Pulmonary Artery Aneurysm: Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , 2012, 2012, 1-5. | 0.3 | 22 |
| 297 | Updating Clinical Endpoint Definitions. <i>Pulmonary Circulation</i> , 2013, 3, 206-216. | 0.8 | 22 |
| 298 | Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 509-519. | 0.3 | 22 |
| 299 | A novel non-invasive and echocardiography-derived method for quantification of right ventricular pressure-volume loops. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 498-507. | 0.5 | 22 |
| 300 | Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. <i>EClinicalMedicine</i> , 2021, 34, 100822. | 3.2 | 22 |
| 301 | Air Travel Can Be Safe and Well Tolerated in Patients with Clinically Stable Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 239-243. | 0.8 | 21 |
| 302 | Riociguat for Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 2266-2268. | 13.9 | 21 |
| 303 | Pulmonary Hemodynamic Response to Exercise in Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy. <i>Respiration</i> , 2015, 90, 63-73. | 1.2 | 21 |
| 304 | Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019, 54, 1900342. | 3.1 | 21 |
| 305 | Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1456. | 1.0 | 21 |
| 306 | Right ventricular pressure-volume loop shape and systolic pressure change in pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L715-L725. | 1.3 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension. <i>Circulation</i> , 2022, 145, 916-933. | 1.6 | 21 |
| 308 | Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 296, L462-L469. | 1.3 | 20 |
| 309 | Effects of hypercapnia and NO synthase inhibition in sustained hypoxic pulmonary vasoconstriction. <i>Respiratory Research</i> , 2012, 13, 7. | 1.4 | 20 |
| 310 | Short-term Improvement in Pulmonary Hemodynamics is Strongly Predictive of Long-term Survival in Patients with Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 523-532. | 0.8 | 20 |
| 311 | Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. <i>International Journal of Cardiology</i> , 2016, 223, 821-826. | 0.8 | 20 |
| 312 | The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 505-513. | 0.8 | 20 |
| 313 | Severe Emphysema in the SU5416/Hypoxia Rat Model of Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 515-518. | 2.5 | 20 |
| 314 | Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 346-356. | 1.4 | 20 |
| 315 | Zardaverine and aerosolised iloprost in a model of acute respiratory failure. <i>European Respiratory Journal</i> , 2003, 22, 342-347. | 3.1 | 19 |
| 316 | Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 63-68. | 1.7 | 19 |
| 317 | Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 194-202. | 0.3 | 19 |
| 318 | Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. <i>Clinical Research in Cardiology</i> , 2017, 106, 776-783. | 1.5 | 18 |
| 319 | Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice. <i>Experimental Physiology</i> , 2017, 102, 180-189. | 0.9 | 18 |
| 320 | Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L792-L800. | 1.3 | 17 |
| 321 | Comparison of Pharmacokinetics and Vasodilatory Effect of Nebulized and Infused Iloprost in Experimental Pulmonary Hypertension: Rapid Tolerance Development. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2006, 19, 353-363. | 1.2 | 17 |
| 322 | Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. <i>Respiratory Research</i> , 2011, 12, 87. | 1.4 | 17 |
| 323 | Effects of Dimethylarginine Dimethylaminohydrolase-1 Overexpression on the Response of the Pulmonary Vasculature to Hypoxia. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 491-500. | 1.4 | 17 |
| 324 | Nintedanib in Severe Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 808-810. | 2.5 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Right ventricular function in pulmonary (arterial) hypertension. <i>Herz</i> , 2019, 44, 509-516. | 0.4 | 17 |
| 326 | FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction. <i>Basic Research in Cardiology</i> , 2020, 115, 17. | 2.5 | 17 |
| 327 | Amelioration of elastase-induced lung emphysema and reversal of pulmonary hypertension by pharmacological iNOS inhibition in mice. <i>British Journal of Pharmacology</i> , 2021, 178, 152-171. | 2.7 | 17 |
| 328 | Apical, But Not Basolateral, Endotoxin Preincubation Protects Alveolar Epithelial Cells Against Hydrogen Peroxide-Induced Loss of Barrier Function: The Role of Nitric Oxide Synthesis. <i>Journal of Immunology</i> , 2002, 169, 1474-1481. | 0.4 | 16 |
| 329 | Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. <i>BMC Pulmonary Medicine</i> , 2011, 11, 56. | 0.8 | 16 |
| 330 | Cofilin, a hypoxia-regulated protein in murine lungs identified by 2D-DE: Role of the cytoskeletal protein cofilin in pulmonary hypertension. <i>Proteomics</i> , 2013, 13, 75-88. | 1.3 | 16 |
| 331 | The Prognostic Significance of Inspiratory Capacity in Pulmonary Arterial Hypertension. <i>Respiration</i> , 2014, 88, 24-30. | 1.2 | 16 |
| 332 | Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 880-889. | 0.3 | 16 |
| 333 | Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. <i>Clinical Research in Cardiology</i> , 2017, 106, 174-182. | 1.5 | 16 |
| 334 | Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. <i>Respiratory Research</i> , 2019, 20, 208. | 1.4 | 16 |
| 335 | Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing. <i>Cardiovascular Research</i> , 2019, 115, 1217-1227. | 1.8 | 16 |
| 336 | Association of right atrial conduit phase with right ventricular lusitropic function in pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 633-642. | 0.7 | 16 |
| 337 | Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 51. | 1.1 | 16 |
| 338 | Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. <i>European Respiratory Review</i> , 2021, 30, 210059. | 3.0 | 16 |
| 339 | AMBRISENTAN HAS NO CLINICALLY RELEVANT EFFECT ON THE PHARMACOKINETICS OR PHARMACODYNAMICS OF WARFARIN. <i>Chest</i> , 2006, 130, 256S. | 0.4 | 15 |
| 340 | Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. <i>BMC Pharmacology</i> , 2009, 9, . | 0.4 | 15 |
| 341 | Update on Pulmonary Hypertension 2009. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1020-1026. | 2.5 | 15 |
| 342 | Sildenafil versus Nitric Oxide for Acute Vasodilator Testing in Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2015, 5, 305-312. | 0.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI ₂) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 401-408. | 0.3 | 15 |
| 344 | Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study. <i>Pulmonary Circulation</i> , 2020, 10, 1-3. | 0.8 | 15 |
| 345 | Risk assessment in severe pulmonary hypertension due to interstitial lung disease. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1118-1125. | 0.3 | 15 |
| 346 | CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 1901192. | 3.1 | 15 |
| 347 | Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?. <i>Histology and Histopathology</i> , 2013, 28, 691-9. | 0.5 | 15 |
| 348 | 2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. <i>Russian Journal of Cardiology</i> , 2016, , 5-64. | 0.4 | 15 |
| 349 | Increase in alveolar antioxidant levels in hyperoxic and anoxic ventilated rabbit lungs during ischemia. <i>Free Radical Biology and Medicine</i> , 2004, 36, 78-89. | 1.3 | 14 |
| 350 | Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension. <i>Frontiers in Pediatrics</i> , 2015, 3, 63. | 0.9 | 14 |
| 351 | Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels. <i>Experimental Physiology</i> , 2018, 103, 1185-1191. | 0.9 | 14 |
| 352 | Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-5. | 0.8 | 14 |
| 353 | Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2020, 9, 4023. | 1.0 | 14 |
| 354 | Modulating cGMP to Treat Lung Diseases. <i>Handbook of Experimental Pharmacology</i> , 2009, , 469-483. | 0.9 | 14 |
| 355 | Nebulization of the acidified sodium nitrite formulation attenuates acute hypoxic pulmonary vasoconstriction. <i>Respiratory Research</i> , 2010, 11, 81. | 1.4 | 13 |
| 356 | Electrophysiological Studies in Patients with Pulmonary Hypertension: A Retrospective Investigation. <i>BioMed Research International</i> , 2014, 2014, 1-6. | 0.9 | 13 |
| 357 | Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 348-355. | 0.3 | 13 |
| 358 | Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2015, 26, 155-162. | 0.3 | 13 |
| 359 | Response by Tello et al to Letter Regarding Article, "Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension". <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e010059. | 1.3 | 13 |
| 360 | Acute Hemodynamic Effects of Nebulized Iloprost via the Neb Adaptive Aerosol Delivery System in Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2015, 5, 162-170. | 0.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Prognostic Relevance of Nonsustained Ventricular Tachycardia in Patients with Pulmonary Hypertension. <i>BioMed Research International</i> , 2016, 2016, 1-7. | 0.9 | 12 |
| 362 | Heart rate response during 6-minute walking testing predicts outcome in operable chronic thromboembolic pulmonary hypertension. <i>BMC Pulmonary Medicine</i> , 2016, 16, 96. | 0.8 | 12 |
| 363 | Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. <i>BMC Pulmonary Medicine</i> , 2016, 16, 5. | 0.8 | 12 |
| 364 | Hypoxic Pulmonary Vasoconstriction-Triggered by an Increase in Reactive Oxygen Species?. <i>Novartis Foundation Symposium</i> , 0, , 196-213. | 1.2 | 12 |
| 365 | Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 400-410. | 0.3 | 12 |
| 366 | Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 345-355. | 0.3 | 12 |
| 367 | Animal models of pulmonary hypertension: role in translational research. <i>Drug Discovery Today: Disease Models</i> , 2010, 7, 89-97. | 1.2 | 11 |
| 368 | A retrospective review of long anterior fusions to the sacrum. <i>Spine Journal</i> , 2011, 11, 290-294. | 0.6 | 11 |
| 369 | Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Respiratory Medicine</i> , 2017, 129, 124-129. | 1.3 | 11 |
| 370 | Enhanced circulating levels of CD3 cells-derived extracellular vesicles in different forms of pulmonary hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-4. | 0.8 | 11 |
| 371 | SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension. <i>Biomarkers</i> , 2020, 25, 290-295. | 0.9 | 11 |
| 372 | Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. <i>Blood</i> , 2021, 137, 2681-2693. | 0.6 | 11 |
| 373 | Stem cell-mediated natural tissue engineering. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 52-62. | 1.6 | 10 |
| 374 | Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 338-347. | 0.3 | 10 |
| 375 | Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007653. | 1.3 | 10 |
| 376 | Cologne consensus conference on pulmonary hypertension – Update 2018. <i>International Journal of Cardiology</i> , 2018, 272, 1-3. | 0.8 | 10 |
| 377 | Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. <i>PLoS ONE</i> , 2016, 11, e0165982. | 1.1 | 10 |
| 378 | Inhaled Iloprost Improves Right Ventricular Load-independent Contractility in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 111-114. | 2.5 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 379 | Synergism of alveolar endotoxin "priming" and intravascular exotoxin challenge in lung injury.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 460-468. | 2.5 | 9 |
| 380 | Measurement of exhaled hydrogen peroxide from rabbit lungs. Biological Chemistry, 2004, 385, 259-264. | 1.2 | 9 |
| 381 | Prostanoids and Phosphodiesterase Inhibitors in Experimental Pulmonary Hypertension. Current Topics in Developmental Biology, 2005, 67, 251-284. | 1.0 | 9 |
| 382 | Effects of carbon monoxide-releasing molecules on pulmonary vasoreactivity in isolated perfused lungs. Journal of Applied Physiology, 2016, 120, 271-281. | 1.2 | 9 |
| 383 | Altered proteasome function in right ventricular hypertrophy. Cardiovascular Research, 2019, 116, 406-415. | 1.8 | 9 |
| 384 | Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population. Frontiers in Physiology, 2019, 10, 54. | 1.3 | 9 |
| 385 | Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. Pulmonary Circulation, 2020, 10, 1-16. | 0.8 | 9 |
| 386 | Evaluation of pulmonary hypertension by right heart catheterisation: does timing matter?. European Respiratory Journal, 2020, 56, 1901892. | 3.1 | 9 |
| 387 | Cytochrome P450 epoxygenase-derived 5,6-epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. Acta Physiologica, 2020, 230, e13521. | 1.8 | 9 |
| 388 | Impact of SARS-CoV-2-Pandemic on Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2021, 12, 668647. | 1.3 | 9 |
| 389 | PINK1-mediated Mitophagy Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 226-228. | 1.4 | 9 |
| 390 | Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study. , 2017, , . | | 9 |
| 391 | Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. Oncotarget, 2017, 8, 29613-29624. | 0.8 | 9 |
| 392 | Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1550-1554. | 2.5 | 8 |
| 393 | Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095. | 0.9 | 8 |
| 394 | Multibeat Right Ventricular Arterial Coupling during a Positive Acute Vasoreactivity Test. American Journal of Respiratory and Critical Care Medicine, 2019, 199, e41-e42. | 2.5 | 8 |
| 395 | Genetic deletion of p66shc and/or cyclophilin D results in decreased pulmonary vascular tone. Cardiovascular Research, 2022, 118, 305-315. | 1.8 | 8 |
| 396 | Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry. Cardiovascular Diagnosis and Therapy, 2021, 11, 1255-1268. | 0.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 397 | The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension. PLoS ONE, 2016, 11, e0152580. | 1.1 | 8 |
| 398 | Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 826369. | 1.1 | 8 |
| 399 | Subthreshold doses of nebulized prostacyclin and rolipram synergistically protect against lung ischemia-reperfusion. Transplantation, 2003, 75, 814-821. | 0.5 | 7 |
| 400 | Resistant Hypertension. Cardiology Clinics, 2015, 33, 75-87. | 0.9 | 7 |
| 401 | Relevance of Angiotensin II and Soluble P-selectin Levels in Patients with Pulmonary Arterial Hypertension Receiving Combination Therapy with Oral Treprostinil: A FREEDOM-2 Biomarker Substudy. Pulmonary Circulation, 2016, 6, 516-523. | 0.8 | 7 |
| 402 | The prognostic relevance of oxygen uptake in inoperable chronic thromboembolic pulmonary hypertension. Clinical Respiratory Journal, 2017, 11, 682-690. | 0.6 | 7 |
| 403 | IRAG1 Deficient Mice Develop PKG1 β Dependent Pulmonary Hypertension. Cells, 2020, 9, 2280. | 1.8 | 7 |
| 404 | Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation. European Respiratory Journal, 2022, 60, 2103087. | 3.1 | 7 |
| 405 | Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. Thrombosis and Haemostasis, 2006, 95, 720-7. | 1.8 | 7 |
| 406 | Hypoxic pulmonary vasoconstriction-triggered by an increase in reactive oxygen species?. Novartis Foundation Symposium, 2006, 272, 196-208; discussion 208-17. | 1.2 | 7 |
| 407 | Prevalence of Mental Disorders in Patients With Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Psychiatry, 2022, 13, 821466. | 1.3 | 7 |
| 408 | Mitochondrial Respiration in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2022, 11, 4132. | 1.0 | 7 |
| 409 | Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2014, 28, 87-89. | 1.1 | 6 |
| 410 | Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension. BMC Pulmonary Medicine, 2015, 15, 11. | 0.8 | 6 |
| 411 | Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study. Respiratory Medicine, 2017, 132, 50-55. | 1.3 | 6 |
| 412 | Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH. Pulmonary Circulation, 2020, 10, 1-12. | 0.8 | 6 |
| 413 | Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-5. | 0.8 | 6 |
| 414 | Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodeling in pulmonary hypertension. Biomarkers in Medicine, 2021, 15, 1021-1034. | 0.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | Effects Of Inhaled Awiptadil (Vasoactive Intestinal Peptide) In Patients With Pulmonary Arterial Hypertension (PAH). , 2010, , . | | 5 |
| 416 | Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): 1-Year Results from the CHEST-2 Long-term Extension Study. Chest, 2013, 144, 1023A. | 0.4 | 5 |
| 417 | Response to Letters Regarding Article, "Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPETE)" Circulation, 2014, 130, e110-2. | 1.6 | 5 |
| 418 | COPD-associated pulmonary hypertension: clinical implications and current methods for treatment. Expert Review of Respiratory Medicine, 2016, 10, 755-766. | 1.0 | 5 |
| 419 | Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial. Pulmonary Circulation, 2018, 8, 1-7. | 0.8 | 5 |
| 420 | Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice. International Journal of Molecular Sciences, 2020, 21, 9099. | 1.8 | 5 |
| 421 | Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice. Respiratory Research, 2020, 21, 136. | 1.4 | 5 |
| 422 | Yarsagumba is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties. Medicina (Lithuania), 2020, 56, 131. | 0.8 | 5 |
| 423 | Right ventricular dyssynchrony: from load-independent right ventricular function to wall stress in severe pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 204589402092575. | 0.8 | 5 |
| 424 | Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart. Clinical Research in Cardiology, 2022, 111, 393-405. | 1.5 | 5 |
| 425 | Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension. European Respiratory Journal, 2022, 60, 2101698. | 3.1 | 5 |
| 426 | Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study. Frontiers in Psychiatry, 2021, 12, 781532. | 1.3 | 5 |
| 427 | Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres. ESC Heart Failure, 2022, 9, 2873-2885. | 1.4 | 5 |
| 428 | Cologne Consensus Conference on pulmonary hypertension. International Journal of Cardiology, 2011, 154, S1-S2. | 0.8 | 4 |
| 429 | Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study. Chest, 2013, 144, 1024A. | 0.4 | 4 |
| 430 | Long-term Riociguat Treatment in Inoperable and Persistent/Recurrent CTEPH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 16-Week Phase III CHEST-1 Study and CHEST-2 Open-Label Extension. Chest, 2014, 145, 535B. | 0.4 | 4 |
| 431 | Reply to Bogaard et al.: Emphysema Is "at the Most" Only a Mild Phenotype in the Sugden/Hypoxia Rat Model of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1450-1452. | 2.5 | 4 |
| 432 | Acute response to rapid iloprost inhalation using the Breelibâ,ç nebulizer in pulmonary arterial hypertension: the Breelibâ,ç acute study. Pulmonary Circulation, 2019, 9, 1-3. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 433 | Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1502. | 1.8 | 4 |
| 434 | Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension. <i>Chest</i> , 2014, 145, 513A. | 0.4 | 3 |
| 435 | Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH). <i>Chest</i> , 2015, 148, 961A. | 0.4 | 3 |
| 436 | Selexipag for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1825-1834. | 0.9 | 3 |
| 437 | Measures of subclinical cardiac dysfunction and increased filling pressures associate with pulmonary arterial pressure in the general population: results from the population-based Rotterdam Study. <i>European Journal of Epidemiology</i> , 2018, 33, 403-413. | 2.5 | 3 |
| 438 | Pulmonary Vascular Pressure Response to Acute Cold Exposure in Kyrgyz Highlanders. <i>High Altitude Medicine and Biology</i> , 2019, 20, 375-382. | 0.5 | 3 |
| 439 | Cardiopulmonary haemodynamics in portopulmonary hypertension. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 556-558. | 5.2 | 3 |
| 440 | Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. <i>Communications Biology</i> , 2021, 4, 1002. | 2.0 | 3 |
| 441 | Exercise Hemodynamic Profiling Is Associated With Outcome in Patients Undergoing Percutaneous Mitral Valve Repair. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010453. | 1.4 | 3 |
| 442 | Clinical Relevance of Right Atrial Functional Response to Treatment in Pulmonary Arterial Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 775039. | 1.1 | 3 |
| 443 | Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH). <i>BMC Pharmacology</i> , 2009, 9, . | 0.4 | 2 |
| 444 | Long Term Use Of Imatinib In Patients With Severe Pulmonary Arterial Hypertension. , 2010, , . | | 2 |
| 445 | Riociguat in Combination With Prostacyclin Analogs for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of the PATENT Studies. <i>Chest</i> , 2015, 148, 922A. | 0.4 | 2 |
| 446 | Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S163. | 0.3 | 2 |
| 447 | Inspiratory capacity is not altered in operable chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 543-546. | 0.8 | 2 |
| 448 | Beyond interleukin-6 in right ventricular function: Evidence for another biomarker. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 674-675. | 0.3 | 2 |
| 449 | Stem/Progenitor Cells in Cardiopulmonary Health, Disease, and Treatment. <i>Stem Cells International</i> , 2019, 2019, 1-4. | 1.2 | 2 |
| 450 | Metabolic Reprogramming in Congenital Cyanotic Heart Disease: Another Fight in Puberty?. <i>Circulation</i> , 2021, 143, 2273-2276. | 1.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 451 | Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. , 2015, , . | | 2 |
| 452 | Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. , 2018, , . | | 2 |
| 453 | Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 812812. | 1.3 | 2 |
| 454 | IMATINIB MESYLATE TREATMENT FOR SEVERE PULMONARY ARTERIAL HYPERTENSION: A PROPOSED PHASE III 24-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL. <i>Chest</i> , 2009, 136, 64S. | 0.4 | 1 |
| 455 | Effects Of Riociguat On Pulmonary Vascular Remodeling In Severe Experimental Pulmonary Hypertension. , 2011, , . | | 1 |
| 456 | Improvement of right heart structure and function by BAY 41-8543 in pulmonary artery banded mice. <i>BMC Pharmacology</i> , 2011, 11, . | 0.4 | 1 |
| 457 | Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan. <i>Chest</i> , 2013, 144, 879A. | 0.4 | 1 |
| 458 | Effects of Riociguat in Treatment-Naive vs Pretreated Patients With Pulmonary Arterial Hypertension: 2-Year Efficacy Results From the PATENT-2 Study. <i>Chest</i> , 2016, 150, 1162A. | 0.4 | 1 |
| 459 | Follow-Up (Measurement) of Corrected QT Interval in Adult Patients before and after Lung Transplantation. <i>BioMed Research International</i> , 2017, 2017, 1-5. | 0.9 | 1 |
| 460 | Reply to "œœ pediatric perspective on the TAPSE/PASP ratio in pulmonary arterial hypertension"œœ. <i>International Journal of Cardiology</i> , 2019, 278, 240-241. | 0.8 | 1 |
| 461 | Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?. <i>Lancet Respiratory Medicine</i> , 2019, 7, 191-193. | 5.2 | 1 |
| 462 | Phosphodiesterase-5 Inhibitors in Pulmonary Arterial Hypertension. , 0, , 105-125. | | 1 |
| 463 | Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 821468. | 1.3 | 1 |
| 464 | Schwere pulmonale Hypertonie - Vasodilative Therapie in der Lungenstrombahn. <i>Pneumologie</i> , 2000, 54, 160-169. | 0.1 | 0 |
| 465 | Sildenafil for lung fibrosis and pulmonary hypertension. <i>Lancet</i> , 2003, 361, 263. | 6.3 | 0 |
| 466 | Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure. <i>European Respiratory Review</i> , 2008, 17, 72-73. | 3.0 | 0 |
| 467 | Response to Letter Regarding Article, "œœPulmonary Vascular Disease in the Developing World"œœ. <i>Circulation</i> , 2009, 120, . | 1.6 | 0 |
| 468 | Phosphodiesterase 10A Upregulation Contributes To Pulmonary Vascular Remodeling. , 2010, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 469 | Role of Reactive Oxygen Species in Acute Pulmonary Oxygen Sensing. <i>Free Radical Biology and Medicine</i> , 2010, 49, S48. | 1.3 | 0 |
| 470 | Exercise Induced Pulmonary Hypertension Associated With Systemic Sclerosis: Four Distinct Entities. , 2010, , . | | 0 |
| 471 | Effects Of The Multikinase Inhibitor Sunitinib On Right Ventricular Remodeling In An Experimental Model Of Right Heart Hypertrophy. , 2010, , . | | 0 |
| 472 | Does Sitaxsentan Therapy Offer Benefit To Functional Class II Patients With Pulmonary Arterial Hypertension. , 2010, , . | | 0 |
| 473 | Reversal Of Experimental Pulmonary Hypertension By The Multi-kinase Inhibitor Sunitinib. , 2010, , . | | 0 |
| 474 | Combined Inhibition Of 5-HT2a And 5-HT2b-receptor Ameliorates Myocardial Hypertrophy And Diastolic Dysfunction In The Pressure Overloaded Right Heart. , 2010, , . | | 0 |
| 475 | A Highly Selective Endothelin-A Receptor Antagonist TBC3711 Reverses Monocrotaline Induced Pulmonary Hypertension. , 2010, , . | | 0 |
| 476 | Combination Therapy With Sildenafil And Sitaxentan In Patients With Severe Pulmonary Hypertension. , 2011, , . | | 0 |
| 477 | Role Of Notch Signaling In Pulmonary Arterial Hypertension. , 2011, , . | | 0 |
| 478 | Prevention Of Experimental Hypoxia-Induced Pulmonary Hypertension By Moderate Exercise Training In Mice. , 2011, , . | | 0 |
| 479 | Mitochondrial Alterations Of Pulmonary Arterial Smooth Muscle Cells In Pulmonary Hypertension. , 2011, , . | | 0 |
| 480 | Contribution Of Progenitor Cells In Experimental Right Heart Hypertrophy Induced By Pulmonary Artery Ligation. , 2011, , . | | 0 |
| 481 | Effects Of The Soluble Guanylate Cyclase Stimulator Riociguat On Emphysema Development In Tobacco-Smoke Exposed Mice. , 2011, , . | | 0 |
| 482 | Effects of riociguat in severe experimental pulmonary hypertension. <i>BMC Pharmacology</i> , 2011, 11, . | 0.4 | 0 |
| 483 | The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. <i>BMC Pharmacology</i> , 2011, 11, . | 0.4 | 0 |
| 484 | Do parameters of cardiac function predict long-term outcomes in patients with pulmonary arterial hypertension? Data from SERAPHIN, a randomized controlled study of macitentan. <i>Chest</i> , 2013, 144, 870B. | 0.4 | 0 |
| 485 | Application of REVEAL Risk Score to Patients With PAH Receiving Riociguat in the PATENT-2 Study. <i>Chest</i> , 2015, 148, 930A. | 0.4 | 0 |
| 486 | The Clinical Impact of Referral Time in Patients With Pulmonary Hypertension on Disease Progression: A Register Analysis of a Tertiary Referral Center. <i>Chest</i> , 2016, 150, 1169A. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 487 | Tidal Carbon Dioxide as a Prognostic Feature in Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1603-1604. | 1.5 | 0 |
| 488 | Effect of Riociguat on Pulmonary Arterial Compliance in Patients With Pulmonary Arterial Hypertension (PAH) in the Respite Study. <i>Chest</i> , 2017, 152, A1005-A1006. | 0.4 | 0 |
| 489 | Response to: Comment on "Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding". <i>BioMed Research International</i> , 2018, 2018, 1-2. | 0.9 | 0 |
| 490 | EFFECT OF RIOCIQUAT ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. <i>Chest</i> , 2018, 154, 1065A-1066A. | 0.4 | 0 |
| 491 | EFFECT OF RIOCIQUAT ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. <i>Chest</i> , 2018, 154, 1062A-1064A. | 0.4 | 0 |
| 492 | Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S96. | 0.3 | 0 |
| 493 | Reply to "Risk stratification in PH associated with interstitial lung disease: The Holy Grail?". <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 317. | 0.3 | 0 |
| 494 | NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. , 2004, , 163-168. | | 0 |
| 495 | Classical transient receptor potential channel 6 (TRPC6) is essential for ischemia-reperfusion injury of the lung. <i>FASEB Journal</i> , 2010, 24, 591.2. | 0.2 | 0 |
| 496 | Definition, Klassifikation und Diagnose der pulmonalen Hypertonie (PH). <i>Atemwegs- Und Lungenkrankheiten</i> , 2015, 41, 166-170. | 0.0 | 0 |
| 497 | Chronisch thromboembolische pulmonale Hypertonie. <i>Atemwegs- Und Lungenkrankheiten</i> , 2015, 41, 198-203. | 0.0 | 0 |
| 498 | Therapie der pulmonal-arteriellen Hypertonie. <i>Atemwegs- Und Lungenkrankheiten</i> , 2015, 41, 171-178. | 0.0 | 0 |
| 499 | Effects of apoptosis signal-regulating kinase 1 (ASK1) inhibition in experimental pressure overload-induced right ventricular dysfunction. , 2015, , . | | 0 |
| 500 | Procedural safety of a fully implantable pump for delivery of intravenous prostanoids in severe pulmonary hypertension: A two-center observational study. , 2016, , . | | 0 |
| 501 | Anti-fibrotic effects of pirfenidone on pulmonary arterial vascular smooth muscle cells. , 2016, , . | | 0 |
| 502 | Pulmonary arterial hypertension-related morbidity is prognostic for survival: insights from the SERAPHIN and GRIPHON studies. , 2017, , . | | 0 |
| 503 | VENTASWITCH study: Switching from Ventavis (iloprost) V10 to V20 improves inhalation behaviour in patients with pulmonary arterial hypertension (PAH). , 2017, , . | | 0 |
| 504 | Effects on Right Ventricular size and function by Riociguat in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (The RIVER Study). , 2018, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 505 | PEGASUS - the effects of commercial air travel on patients suffering from pulmonary hypertension - a prospective, multicenter, multinational study. , 2018, , . | | 0 |
| 506 | Acute response of iloprost inhalation using the Breelib nebulizer in pulmonary arterial hypertension: the Breelib acute study. , 2018, , . | | 0 |
| 507 | Effects of electronic cigarette aerosol on isolated murine lung cells and bronchoalveolar lavage fluid. , 2018, , . | | 0 |
| 508 | Diagnostic accuracy of echocardiography in pulmonary hypertension due to interstitial lung disease. , 2018, , . | | 0 |
| 509 | EARLIER: End tidal carbon dioxide for earlier detection of pulmonary hypertension. , 2018, , . | | 0 |
| 510 | Childhood Trauma in Patients With PAHâ€™ Prevalence, Impact on QoL, and Mental Healthâ€™ A Preliminary Report. Frontiers in Psychiatry, 2022, 13, 812862. | 1.3 | 0 |